908 Devices earnings release, August 11, 2026

908 Devices Inc. (MASS) · Form 8-K, Item 2.02 · Filed · SEC filing

​

​

908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook

Revenue increased 23% compared to prior year

Updated full year 2026 outlook reflects 21% to 25% year-over-year growth

​

BURLINGTON, Mass. – August 11, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended June 30, 2026.

​

“We delivered another strong quarter, growing revenue 23% year-over-year, while narrowing our Adjusted EBITDA loss by more than half compared to a year ago,” said Kevin J. Knopp, CEO and Co-founder. “Our momentum with U.S. state and local customers remained particularly strong, representing more than half of our revenue, as agencies modernize to address today's threats and hazards. Our newest FTIR product, VipIR, is leading that charge, and we surpassed our 100th unit shipped since launch. With the same commercial channel behind that momentum, we are now introducing NIRLab to the U.S. market. In just our first 60 days since deal close, we have engaged hundreds of prospects nationwide across more than 30 agencies. With a robust pipeline of opportunities, we are confident in our team's ability to deliver, and we remain committed to the disciplined execution of our strategy.”

​

Recent Highlights

​

Second Quarter 2026 Financial Results

​

Revenue was $16.1 million for the three months ended June 30, 2026, a 23% increase over the prior year period, driven by an increase in product revenue for VipIR and the addition of NIRLab revenue. The installed base grew 23% year-over-year to 4,101 devices, with 198 devices placed during the second quarter. Recurring revenue represented 31% of total revenues in the quarter.

​

Gross profit was $8.3 million for the second quarter of 2026, compared to $6.4 million for the corresponding period in the prior year. GAAP gross margin was 52% as compared to 49% for the corresponding prior year period. Adjusted gross profit was $9.2 million for the second quarter of 2026, compared to $7.3 million for the corresponding period in the prior year. Adjusted gross margin was 57%, as compared to 56% for the corresponding prior year period. The increase in adjusted gross margin percentage was primarily driven by higher product revenues, including a shift in channel mix.

​

Operating expenses were $21.2 million for the second quarter of 2026, compared to $21.5 million for the corresponding prior year period. The decrease of $0.3 million includes a noncash decrease of $0.3 million related to a change in the fair value of the contingent consideration liability.

​

Net loss from continuing operations was $11.9 million for the second quarter of 2026, compared to a net loss from continuing operations of $12.9 million for the corresponding prior year period. Adjusted EBITDA was a loss of $1.9 million for the second quarter of 2026, compared to a loss of $3.9 million for the corresponding period in the prior year.

​

Net loss attributable to common stockholders was $11.9 million for the second quarter of 2026, compared to $13.3 million for the corresponding prior year period.

​

Cash, cash equivalents and marketable securities were $101.5 million as of June 30, 2026, with no debt outstanding. In the second quarter of 2026, $13.5 million of cash and cash equivalents were used for the acquisition of NIRLAB SA and $3.5 million was received from the release of the escrow from the desktop divestiture.

​

2026 Guidance

​

908 Devices updates its full year revenue guidance range to $68.0 million to $70.0 million (from $67.0 million to $70.0 million previously), raising the low end of the range and representing 21% to 25% growth compared to 2025 revenue.

​

Webcast Information

​

908 Devices will host a conference call to discuss the second quarter 2026 financial results before market open on Tuesday, August 11, 2026 at 8:30 am Eastern Time. A webcast of the conference call can be accessed in the Investor Relations section of 908devices.com. The webcast will be archived and available for replay for at least 90 days after the event.

​

About 908 Devices

​

908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit www.908devices.com.

​

Non-GAAP Measures of Financial Performance

​

To supplement the Company’s financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release and presented with detailed reconciliations to comparable GAAP financial results in the tables below:

​

​... (truncated)stry, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness for purposes of comparison. Furthermore, these non-GAAP measures have certain limitations since they do not include the impact of certain expenses and cash flows that are reflected in the Company’s GAAP financial results. Accordingly, when analyzing the Company’s operating performance and guidance, investors should not consider non-GAAP measures in isolation or as a substitute for, or superior to, comparable financial measures prepared in accordance with GAAP. Rather, the Company believes that these non-GAAP financial measures, when viewed in addition to and not in lieu of reported GAAP financial results, provide investors with additional meaningful information to assess financial performance and trends, enable comparison of financial results between periods, and allow for greater transparency with respect to key metrics utilized internally in analyzing and operating the Company’s business.

​

Forward Looking Statements

​

Financial statements

Income Statement

Three Months Ended June 30, — (unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue:Product revenue12,9749,57723,71118,106
Revenue:Service and contract revenue3,1003,4585,7456,707
Revenue:Total revenue16,07413,03529,45624,813
Cost of revenue:Product cost of revenue6,4125,32311,57310,048
Cost of revenue:Service and contract cost of revenue1,3191,3392,6582,850
Cost of revenue:Total cost of revenue7,7316,66214,23112,898
Cost of revenue:Gross profit8,3436,37315,22511,915
Operating expenses:Research and development3,5984,4057,0698,234
Operating expenses:Selling, general and administrative11,11210,33721,02720,576
Operating expenses:Change in fair value of contingent consideration6,4426,79212,8239,291
Operating expenses:Total operating expenses21,15221,53440,91938,101
Operating expenses:Loss from operations-12,809-15,161-25,694-26,186
Operating expenses:Other income, net8612,3241,7913,512
Operating expenses:Loss from continuing operations before income taxes-11,948-12,837-23,903-22,674
Operating expenses:Income tax benefit (expense), net54-7154-71
Operating expenses:Net loss from continuing operations-11,894-12,908-23,849-22,745
Operating expenses:Net income (loss) from discontinued operations, net of tax-39853,042
Operating expenses:Net income (loss) attributable to common stockholders-11,894-13,306-23,84930,297
Operating expenses:Net income (loss) from continuing operations per share attributable to common stockholders, basic and diluted-0.32-0.36-0.64-0.64
Operating expenses:Net income (loss) from discontinued operations per share attributable to common stockholders, basic and diluted$—-0.01$—1.49
Operating expenses:Net income (loss) per share attributable to common stockholders, basic and diluted-0.32-0.37-0.640.85
Weighted average common shares outstandingBasic and diluted37,727,66835,877,94737,275,67135,633,573

Income Statement

Three Months Ended — Reconciliation from Gross Profit (GAAP) to Adjusted Gross Profit (Non-GAAP) and Margin Percentage:

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
Gross Profit (GAAP)8,3436,37315,22511,915
Intangible amortization7346341,3691,269
Acquisition and integration costs50
Restructuring222288
Stock-based compensation107107262223
Adjusted Gross Profit (Non-GAAP)9,1847,33616,85613,745
Gross Margin Percentage (GAAP)52.0%49.0%52.0%48.0%
Adjusted Gross Margin Percentage (Non-GAAP)57.0%56.0%57.0%55.0%

Balance Sheet

December 31, — (unaudited)

June 30, – 2026December 31, – 2025
Current assets:Cash, cash equivalents and marketable securities101,531112,970
Current assets:Accounts receivable, net11,71011,327
Current assets:Inventory14,37212,990
Current assets:Prepaid expenses and other current assets4,4077,272
Current assets:Total current assets132,020144,559
Current assets:Operating lease, right-of-use assets4,0094,397
Current assets:Property and equipment, net4,6054,232
Current assets:Goodwill11,055
Current assets:Intangible, net45,11536,412
Current assets:Other long-term assets734471
Current assets:Total assets197,538190,071
Current liabilities:Accounts payable and accrued expenses8,4728,424
Current liabilities:Deferred revenue10,7118,934
Current liabilities:Operating lease liabilities and other liabilities30,23916,706
Current liabilities:Total current liabilities49,42234,064
Current liabilities:Deferred revenue, net of current portion11,0128,331
Current liabilities:Contingent consideration, net of current portion5,860
Current liabilities:Other long-term liabilities4,4783,977
Current liabilities:Total liabilities70,77246,372
Current liabilities:Total stockholders' equity126,766143,699
Current liabilities:Total liabilities and stockholders' equity197,538190,071
Full release

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth and future business prospects and market opportunities. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission (SEC) which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

​

Investor and Media Contact:

Barbara Russo

IR@908devices.com

​

​

908 DEVICES INC.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

​

​

​

​

​

​

908 DEVICES INC.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

​

​

​

​

​

​

908 DEVICES INC.

Reconciliations of GAAP to Non-GAAP Financial Measures

(Unaudited, amounts in thousands, except percentage and per share data)

In all tables below, totals may not add due to rounding

​

​

​

Reconciliation from Gross Profit (GAAP) to Adjusted Gross Profit (Non-GAAP) and Margin Percentage:

​

​

​

​

Reconciliation from Net Income (Loss) from Continuing Operations (GAAP) to Adjusted EBITDA (Non-GAAP):

​

​

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · 908 Devices earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.